{"id":"W3217140412","doi":"10.1016/j.ygyno.2020.05.070","title":"ENGOT-ov43/keylynk-001: A phase III, placebo- and active-controlled trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of advanced BRCA-nonmutated epithelial ovarian cancer","year":2020,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Olaparib; Pembrolizumab; Oncology; Internal medicine; PARP inhibitor; Ovarian cancer; Carboplatin; Chemotherapy; Regimen; BRCA mutation; Placebo; Gynecology; Cancer; Immunotherapy; Poly ADP ribose polymerase; Cisplatin; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001473725,0.001658472,0.002423451,0.0005170795,0.0004381615,0.001296827,0.001143115,0.00155287,0.007653783],"category_scores_gemma":[0.000990952,0.0006268033,0.001555386,0.000430931,0.001166212,0.001227239,0.0003085192,0.004647134,0.001267643],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009484694,"about_ca_system_score_gemma":0.001301244,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001532082,"about_ca_topic_score_gemma":0.004730937,"domain_scores_codex":[0.999684,0.0001316717,0.0000138895,0.00006574193,0.00002291346,0.00008179281],"domain_scores_gemma":[0.9995986,0.00007838235,0.00006748189,0.00003145328,0.00002103894,0.0002030795],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8892689,0.01844676,0.000995619,0.00188961,0.001944265,0.00008858956,0.0001332803,0.001048828,0.01297325,0.0005279204,0.004356229,0.06832664],"study_design_scores_gemma":[0.9223697,0.07188028,0.002058303,0.00005024726,0.0004711755,0.0000617023,0.00003808895,0.0005507927,0.0007492703,0.0001899664,0.001559697,0.00002082628],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9737532,0.01009445,0.001129473,0.001758394,0.0009226947,0.003558111,0.003036919,0.0005071848,0.005239587],"genre_scores_gemma":[0.9765866,0.006037364,0.002161049,0.001940192,0.0003457002,0.002991328,0.00308234,0.00008085438,0.006774769],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007653783,"threshold_uncertainty_score":0.02560443,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03260162568201434,"score_gpt":0.348120337627277,"score_spread":0.3155187119452627,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}